Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Go back to Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
(NASDAQ: ARVN) Delayed: 7.64 --0 (-0%)
Previous Close $7.64    52 Week High $ 
Open $7.64    52 Week Low $ 
Day High $7.64    P/E N/A 
Day Low $7.64    EPS $ 
Volume 981